A
179.10
3.32 (1.89%)
| Previous Close | 175.78 |
| Open | 176.00 |
| Volume | 283,535 |
| Avg. Volume (3M) | 500,487 |
| Market Cap | 10,834,511,872 |
| Price / Sales | 23.48 |
| 52 Weeks Range | |
| Earnings Date | 1 Sep 2025 - 5 Sep 2025 |
| Profit Margin | -92.67% |
| Operating Margin (TTM) | -103.23% |
| Diluted EPS (TTM) | -6.86 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | -218.93 M |
| Levered Free Cash Flow (TTM) | -133.44 M |
| Return on Assets (TTM) | -22.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ascendis Pharma A/S | Bullish | Bullish |
AIStockmoo Score
-0.5
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.50 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 113.57% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 280.00 (Evercore ISI Group, 56.34%) | Buy |
| Median | 220.00 (22.84%) | |
| Low | 200.00 (Cantor Fitzgerald, 11.67%) | Buy |
| Average | 229.63 (28.21%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 170.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 03 Jul 2025 | 250.00 (39.59%) | Buy | 174.18 |
| 05 May 2025 | 250.00 (39.59%) | Buy | 170.74 | |
| Oppenheimer | 13 Jun 2025 | 224.00 (25.07%) | Buy | 170.80 |
| B of A Securities | 09 Jun 2025 | 216.00 (20.60%) | Buy | 173.15 |
| 03 Jun 2025 | 201.00 (12.23%) | Buy | 174.40 | |
| Cantor Fitzgerald | 12 May 2025 | 200.00 (11.67%) | Buy | 154.43 |
| Evercore ISI Group | 02 May 2025 | 280.00 (56.34%) | Buy | 172.06 |
| JP Morgan | 02 May 2025 | 245.00 (36.80%) | Buy | 172.06 |
| RBC Capital | 02 May 2025 | 210.00 (17.25%) | Buy | 172.06 |
| 16 Apr 2025 | 205.00 (14.46%) | Buy | 158.15 | |
| Wedbush | 02 May 2025 | 212.00 (18.37%) | Buy | 172.06 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jun 2025 | Announcement | TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial |
| 02 Jun 2025 | Announcement | FDA Accepts TransCon® CNP NDA for Priority Review |
| 29 May 2025 | Announcement | NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA |
| 13 May 2025 | Announcement | New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide) |
| 12 May 2025 | Announcement | New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism |
| 05 May 2025 | Announcement | Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025 |
| 01 May 2025 | Announcement | Ascendis Pharma Reports First Quarter 2025 Financial Results |
| 24 Apr 2025 | Announcement | Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |